Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,672 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM. Lynce F, et al. Among authors: geng x. Breast Cancer Res Treat. 2019 Jun;175(3):595-603. doi: 10.1007/s10549-019-05191-2. Epub 2019 Mar 9. Breast Cancer Res Treat. 2019. PMID: 30852761 Free PMC article. Clinical Trial.
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Asch F, Tan M, Isaacs C, Swain SM. Khoury K, et al. Among authors: geng x. Breast Cancer Res Treat. 2021 Feb;185(3):863-868. doi: 10.1007/s10549-020-06053-y. Epub 2021 Jan 5. Breast Cancer Res Treat. 2021. PMID: 33400034 Free PMC article.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: geng x. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559. medRxiv. 2023. PMID: 38105958 Free PMC article. Updated. Preprint.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: geng x. Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. Nat Commun. 2024. PMID: 38538574 Free PMC article. Clinical Trial.
Pilots' Healthcare Seeking Anxiety When Experiencing Chest Pain.
Hoffman W, Chervu N, Geng X, Üren A. Hoffman W, et al. Among authors: geng x. J Occup Environ Med. 2019 Sep;61(9):e401-e405. doi: 10.1097/JOM.0000000000001662. J Occup Environ Med. 2019. PMID: 31306268 No abstract available.
2,672 results